BNGO Bionano Genomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BNGO

Price (delayed)

$0.95

Market cap

$51.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.81

Enterprise value

$113.02M

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for ...

Highlights
Bionano Genomics's gross profit has soared by 61% YoY and by 7% from the previous quarter
Bionano Genomics's revenue has increased by 30% YoY and by 7% QoQ
The EPS has decreased by 49% YoY but it has increased by 2.2% QoQ
The company's net income has shrunk by 75% YoY and by 2.3% QoQ
BNGO's quick ratio has dropped by 67% year-on-year and by 38% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://bionanogenomics.com
Peers: RVTY QTRX PRPO

Key stats

What are the main financial stats of BNGO
Market
Shares outstanding
54.69M
Market cap
$51.96M
Enterprise value
$113.02M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
0.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.13
Earnings
Revenue
$36.12M
EBIT
-$227.31M
EBITDA
-$213.34M
Free cash flow
-$126.87M
Per share
EPS
-$6.81
Free cash flow per share
-$3.72
Book value per share
$2.48
Revenue per share
$1.06
TBVPS
$5.28
Balance sheet
Total assets
$214.4M
Total liabilities
$118.25M
Debt
$79.41M
Equity
$96.16M
Working capital
$40.09M
Liquidity
Debt to equity
0.83
Current ratio
1.4
Quick ratio
1.12
Net debt/EBITDA
-0.29
Margins
EBITDA margin
-590.7%
Gross margin
26.5%
Net margin
-643.7%
Operating margin
-586.4%
Efficiency
Return on assets
-96.9%
Return on equity
-140.6%
Return on invested capital
-187.4%
Return on capital employed
-198.7%
Return on sales
-629.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BNGO stock price

How has the Bionano Genomics stock price performed over time
Intraday
0%
1 week
20.25%
1 month
-6.86%
1 year
-85.56%
YTD
-49.74%
QTD
-14.41%

Financial performance

How have Bionano Genomics's revenue and profit performed over time
Revenue
$36.12M
Gross profit
$9.57M
Operating income
-$211.8M
Net income
-$232.49M
Gross margin
26.5%
Net margin
-643.7%
The company's net income has shrunk by 75% YoY and by 2.3% QoQ
Bionano Genomics's gross profit has soared by 61% YoY and by 7% from the previous quarter
BNGO's operating income has plunged by 61% YoY but it is up by 7% from the previous quarter
Bionano Genomics's net margin has decreased by 35% YoY but it has increased by 4.8% from the previous quarter

Growth

What is Bionano Genomics's growth rate over time

Valuation

What is Bionano Genomics stock price valuation
P/E
N/A
P/B
0.38
P/S
0.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.13
The EPS has decreased by 49% YoY but it has increased by 2.2% QoQ
BNGO's price to book (P/B) is 91% lower than its 5-year quarterly average of 4.2 and 62% lower than its last 4 quarters average of 1.0
BNGO's equity has plunged by 61% YoY and by 19% from the previous quarter
The P/S is 97% below the 5-year quarterly average of 35.5 and 84% below the last 4 quarters average of 5.6
Bionano Genomics's revenue has increased by 30% YoY and by 7% QoQ

Efficiency

How efficient is Bionano Genomics business performance
Bionano Genomics's return on equity has shrunk by 199% YoY and by 26% QoQ
Bionano Genomics's ROIC has plunged by 182% YoY and by 4.7% from the previous quarter
Bionano Genomics's return on assets has shrunk by 138% YoY and by 12% QoQ
The ROS has decreased by 34% YoY but it has increased by 6% QoQ

Dividends

What is BNGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BNGO.

Financial health

How did Bionano Genomics financials performed over time
BNGO's total assets is 81% greater than its total liabilities
The total liabilities has surged by 104% year-on-year and by 88% since the previous quarter
BNGO's current ratio has dropped by 68% year-on-year and by 46% since the previous quarter
Bionano Genomics's debt is 17% less than its equity
BNGO's equity has plunged by 61% YoY and by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.